Therapies in development for community-acquired pneumonia

Expert Opinion on Investigational Drugs

Volumn 11, Issue 4, 2002, Pages 545-552

  Blasi, Francesco ^a   Braga, Piercarlo ^a   Cazzola, Mario ^a   Cosentini, Roberto ^a   Tarsia, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

lactams; Antimicrobial resistance; Cationic peptides; Fluoroquinolones; glycopeptides; Glycylcyclines; Ketolides; Lipopeptides; Lower respiratory tract infections; Novel compounds; Oxazolidinones; Streptogramins

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BETA LACTAM ANTIBIOTIC; CETHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; EPEREZOLID; ERYTHROMYCIN; GLYCYLCYCLINE DERIVATIVE; KETOLIDE; LINCOSAMIDE DERIVATIVE; LINEZOLID; LIPOPEPTIDE; MACROLIDE; METICILLIN; MOXIFLOXACIN; NEW DRUG; NUCLEIC ACID SYNTHESIS INHIBITOR; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN SYNTHESIS INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BONE MARROW TOXICITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG COST; DRUG CROSS REACTIVITY; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG USE; HOSPITAL INFECTION; HUMAN; INFECTIOUS PNEUMONIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PENICILLIN RESISTANCE; PROTEIN LIPID INTERACTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COMMUNITY-ACQUIRED INFECTIONS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; NUCLEIC ACID SYNTHESIS INHIBITORS; PEPTIDOGLYCAN; PNEUMONIA, BACTERIAL; PROTEIN SYNTHESIS INHIBITORS;

EID: 0036240928     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.4.545     Document Type: Review

References (67)

1. Antimicrobial resistance in Streptococcus pneumoniae: A South African perspective
2. Emergence of multiple antibiotic-resistant Streptococcus pneumoniae in Hong Kong
3. Antimicrobial resistance in Streptococcus pneumoniae: An epidemiological survey in France; 1970-1990
4. Spread of multidrug-resistant Streptococcus pneumoniae in South Korea
5. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program
6. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of β-lactamase-positive strains resistant to amoxicillin-clavulanate: Surveillance study
7. Antimicrobial-drug resistance
8. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella species from intensive care units in Europe
9. Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistance
10. Pseudomonas aeruginosa outbreak in a burn unit: Role of antimicrobials in the emergence of multiply resistant strains
11. Clinical importance and antibiotic resistance of Acinetobacter spp
12. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics
13. What's new in the antibiotic pipeline
14. Antibiotic resistance: Lessons for the future
15. Research and development of antibacterial agents
16. Ketolides lack inducibility properties of MLSB resistance phenotype
17. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin quinupristin-dalfopristin), a macrolide (erythromycin) and a lincosamide (clindamycin)
18. Telithromycin: A new ketolide antimicrobial for treatment of respiratory tract infection
19. Studies of the novel ketolide ABT-773. Transport, binding to ribosomes and inhibition of protein synthesis of Streptococcus pneumoniae
20. Comparison of the in vitro activity of ABT-773, a novel antibacterial ketolide, with erythromycin and ciprofloxacin against respiratory pathogens
21. Activity of the ketolide ABT-773 against recent North American isolates of Streptococcus pneumoniae
22. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
23. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
24. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
25. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
26. Linezolid resistance in a clinical isolate of Staphylococcus aureus
27. Multi-center in vitro evaluation of linezolid compared with other antibiotics in The Netherlands
28. U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration
29. Inhibition of protein synthesis by streptogramins and related antibiotics
30. Glycyclines: Third-generation tetracycline antibiotics
31. Tetracycline antibiotic: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance
32. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)
33. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens
34. Pharmacodynamics of fluoroquinolones
35. Advances in DNA gyrase inhibitors
36. The tentative BSAC breakpoint of gemifloxacin, a novel fluoroquinolone
37. In vitro activity of gemifloxacin against S. pneumoniae, H. influenzae, M. catarrhalis, L. pneumophila and Chlamydia spp
38. Pharmacokinetic and pharmacodynamic profiles of the new quinolones
39. The renewed challenge of β-lactams to overcome bacterial resistance
40. In vitro activities if J-111,225,J-114,870, J-114,871, novel carbapenems having potent activities against MRSA and Pseudomonas aeruginosa
41. The renewed challenge of antibacterial chemotherapy
42. Beyond vancomycin: New therapies to meet the challenge of glycopeptide resistance
43. Genetics and mechanisms of glycopeptide resistance in enterococci
44. In vitro antibacterial properties of pexiganan, an analog of magainin
45. Protamine-induced permeabilization of cell envelopes of Gram-positive and Gram-negative bacteria
46. Cationic antimicrobial peptide antibiotics
47. Granulysin: A novel antimicrobial
48. Cationic antimicrobial peptide antibiotics
49. Daptomycin: A novel agent for Gram-positive infections
50. In vitro activity of daptomycin against resistant Gram-positive pathogens
51. Comparative in vitro activity of daptomycin versus vancomycin, linezolid, and synercid against methicillin-resistant and susceptible staphylococci, vancomycin-susceptible Staphylococcus aureus
52. In vitro studies on resistance to lipopeptide antibiotic daptomycin
53. Lipoteichoic acid as a new target for activity of antibiotics: Mode of action of daptomycin (LY146032)
54. Daptomycin disrupts membrane potential in growing Staphylococcus aureus
55. Resistance studies with daptomycin
56. Inhibitor-resistant TEM β-lactamases: Phenotypic, genetic and biochemical characteristics
57. β-Lactamase inhibitors: Agents to overcome bacterial resistance
58. Interplay between chromosomal β-lactamase and the MexAB-OprM efflux system in intrinsic resistance to β-lactams in Pseudomonas aeruginosa
59. Bacterial resistance mechanisms as therapeutic targets
60. Deformylase as a novel antibacterial target
61. Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionally on inhibition
62. The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome
63. Antibiotic activity and characterization of BB3497 - A new class of peptide deformylase inhibitor
64. The clinical impact of macrolide resistance in pneumococcal respiratory infections
65. Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: Implication for treatment of community-acquired lower respiratory tract infections
66. Problems and prospectives in the antibiotic treatment of lower respiratory tract infections